Phase 1 proof of concept study of CTX-10726
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs CTX 10726 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- 14 Jan 2025 New trial record
- 08 Jan 2025 According to a Compass Therapeutics media release, company expect to submit an IND by year-end with initial proof-of-concept clinical data in 2026.